Ambagon adds $85M for molecular glues that stick to elusive protein targets


Biotech startup Ambagon Therapeutics is taking a new approach to making elusive protein targets “druggable” by using molecular glues. The biotech has a pipeline of preclinical cancer drugs and it has raised $85 million to support their development.

Leave a Reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.